Instructional design and assessment: Pharmacogenomics training using an instructional software system

American Journal of Pharmaceutical Education

Volumn 75, Issue 2, 2011, Pages

  Springer, John A ^a   Iannotti, Nicholas V ^a   Kane, Michael D ^a,b   Haynes, Kevin ^c   Sprague, Jon E ^b  

^a PURDUE UNIVERSITY   (United States)

^b OHIO NORTHERN UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Drug safety; Instructional software; Personalized medicine; Pharmacogenomics

Indexed keywords

ARTICLE; COMPUTER PROGRAM; CURRICULUM; DRUG SAFETY; EDUCATION; HUMAN; INSTRUCTIONAL SOFTWARE; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PERSONALIZED MEDICINE; PHARMACIST; PHARMACOGENETICS; PHARMACOGENOMICS; PHARMACY STUDENT; PROFESSIONAL STANDARD; TEACHING;

DRUG SAFETY; INSTRUCTIONAL SOFTWARE; PERSONALIZED MEDICINE; PHARMACOGENOMICS;

COMPUTER-ASSISTED INSTRUCTION; CURRICULUM; EDUCATION, PHARMACY; EDUCATIONAL MEASUREMENT; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACISTS; PHARMACOGENETICS; PROFESSIONAL ROLE; SOFTWARE; STUDENTS, PHARMACY;

EID: 79955127977     PISSN: 00029459     EISSN: 15536467     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Veenstra D, Higashi M, Phillips K. Assessing the costeffectiveness of pharmacogenomics. AAPS J. 2000;2(3):e29.
2. Accreditation Standards and Guidelines for the Professional Program in Pharmacy Leading to the Doctor of Pharmacy Degree. The Acceditation Council of Pharmacy Education, Chicago, IL 2007. http://www.acpe-accedit.org/standards/default.asp. Accessed August 5, 2010.
3. Kane MD, Springer JA, Sprague JE. Drug safety assurance through clinical genotyping: near-term considerations for a systems-wide implementation of personalized medicine. Person Med. 2008;5(4):387-397.
4. Hedgecoe A. Context, Ethics and pharmacogenetics. Stud Hist Philos Biol Biomed Sci. 2006;37(3):566-582.
5. Van Delden J, Bolt I, Kalis A, Derijks J, Leufkens H. Tailor-made pharmacotherapy: future developments and ethical challenges in the field of pharmacogenomics. Bioethics. 2004;18(4):303-321.
6. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther. 2008;83(3):460-470.
7. Anderson J, Horne B, Stevens S, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007;116(22):2563-2570.
8. Sullivan-Klose T, Ghanayem B, Bell D, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996;6(4):341-349.
9. Shintani M, Ieiri I, Inoue K, et al. Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clin Pharmacol Ther. 2001;70(2):175-182.
10. Poirier T, Crouch M, Mackinnon G, et al. Updated guidelines for manuscripts describing instructional design and assessment: the IDEAS format. Am J Pharm Educ. 2009;73(3):Article 55.
11. Gilkey M, Earp J, French E. Applying health education theory to patient safety programs: three case studies. Health Promot Pract. 2008;9(2):123-129.